je.st
news
Tag: hepatitis
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
2015-07-24 22:19:25| Biotech - Topix.net
An experimental drug for one of the most difficult-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options for patients with the liver-destroying virus. Daklinza , developed by New York-based Bristol-Myers Squibb Co., is the first drug approved to treat genotype 3 hepatitis C. It's to be used with Sovaldi, one of two blockbuster hepatitis C drugs sold by Gilead Sciences, along with Harvoni.
Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
2015-07-23 17:02:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or 6 infection.1 The EMA will initiate review of the MAA under accelerated assessment timelines. Language: English Contact: Merck & Co., Inc.Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
application
marketing
treatment
Pricey successor overtakes $1,000-per-pill hepatitis C drug
2015-07-13 10:00:43| Biotech - Topix.net
Harvoni, the newest pill from California-based Gilead Sciences, accounted for more than three-fourths of the prescriptions ... . This image provided by Gilead Sciences shows a bottle of the Hepititis drug Harvoni.
Tags: drug
successor
hepatitis
pricey
How Gilead Sciences Is Gouging Hepatitis C Patients, $1,000 a Pill
2015-06-21 20:06:31| Biotech - Topix.net
A new wave of hepatitis C drugs is all the rage. But while these new pills boast cure rates of 90 percent in less time than their predecessors, their prices are causing rage.
Tags: sciences
patients
pill
hepatitis
Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1
2015-06-03 06:35:57| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan
Tags: c
results
study
japanese
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] next »